Compare
Melar Acquisition Corp. I/Cayman vs OptimizeRx Corp vs Janel Corp vs Icts International N V
| Latest fiscal year | Melar Acquisition Corp. I/Cayman MACI | OptimizeRx Corp OPRX | Janel Corp JANL | Icts International N V ICTSF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | n/a | $109.43M | $207.44M | $534.38M |
| Revenue growth (YoY) | n/a | +18.8% | +13.2% | +10.6% |
| Gross margin | n/a | 67.3% | 31.3% | 11.2% |
| Operating margin | n/a | 10.7% | 3.1% | -3.3% |
| Net margin | n/a | 4.7% | 2.7% | -2.7% |
| Net income | $5.54M | $5.13M | $5.66M | -$14.35M |
| EPS (Diluted) | n/a | $0.27 | $4.17 | -$0.40 |
| Operating cash flow | -$774.3K | $18.71M | $43.07M | -$30.99M |
| Free cash flow | n/a | $18.66M | n/a | -$32.80M |
| Cash & equivalents | n/a | $23.36M | n/a | $16.89M |
| Total assets | $175.31M | $176.92M | $170.75M | $165.55M |
| Total liabilities | $10.89M | $48.62M | $144.95M | $99.75M |
| Shareholders' equity | -$6.99M | $128.29M | $25.80M | -$21.23M |
| Return on year-end equity | n/a | 4.0% | 21.9% | n/a |
| Shares outstanding | n/a | 18.76M | 1.19M | 37.43M |
Revenue, most recent five fiscal years
| Fiscal year | Melar Acquisition Corp. I/Cayman | OptimizeRx Corp | Janel Corp | Icts International N V |
|---|---|---|---|---|
| Latest | n/a | $109.43M Ended 2025-12-31 | $207.44M Ended 2025-09-30 | $534.38M Ended 2025-12-31 |
| 1 year earlier | n/a | $92.13M Ended 2024-12-31 | $183.18M Ended 2024-09-30 | $483.31M Ended 2024-12-31 |
| 2 years earlier | n/a | $71.52M Ended 2023-12-31 | $186.45M Ended 2023-09-30 | $431.54M Ended 2023-12-31 |
| 3 years earlier | n/a | $62.45M Ended 2022-12-31 | $316.86M Ended 2022-09-30 | $324.98M Ended 2022-12-31 |
| 4 years earlier | n/a | $61.29M Ended 2021-12-31 | $146.42M Ended 2021-09-30 | $324.93M Ended 2021-12-31 |